Nothing Special   »   [go: up one dir, main page]

EP3504314B1 - Procédés acoustiques associés à des bioréacteurs - Google Patents

Procédés acoustiques associés à des bioréacteurs Download PDF

Info

Publication number
EP3504314B1
EP3504314B1 EP16758359.0A EP16758359A EP3504314B1 EP 3504314 B1 EP3504314 B1 EP 3504314B1 EP 16758359 A EP16758359 A EP 16758359A EP 3504314 B1 EP3504314 B1 EP 3504314B1
Authority
EP
European Patent Office
Prior art keywords
cells
bioreactor
cell culture
standing wave
ultrasonic transducer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP16758359.0A
Other languages
German (de)
English (en)
Other versions
EP3504314A1 (fr
Inventor
Thomas J. Kennedy
Bart Lipkens
Louis Masi
Stanley Kowalski
Chris LEIDEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flodesign Sonics Inc
Original Assignee
Flodesign Sonics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flodesign Sonics Inc filed Critical Flodesign Sonics Inc
Publication of EP3504314A1 publication Critical patent/EP3504314A1/fr
Application granted granted Critical
Publication of EP3504314B1 publication Critical patent/EP3504314B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/02—Separating microorganisms from the culture medium; Concentration of biomass
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D21/00—Separation of suspended solid particles from liquids by sedimentation
    • B01D21/28—Mechanical auxiliary equipment for acceleration of sedimentation, e.g. by vibrators or the like
    • B01D21/283—Settling tanks provided with vibrators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/04—Cell isolation or sorting

Definitions

  • a modern bioreactor is a very complicated piece of equipment. It provides for, among other parameters, the regulation of fluid flow rates, gas content, temperature, pH and oxygen content. All of these parameters can be tuned to allow the cell culture to be as efficient as possible of producing the desired biomolecules from the bioreactor process.
  • One process for using a bioreactor field is the perfusion process. The perfusion process is distinguished from the fed-batch process by its lower capital cost and higher throughput.
  • a culture is seeded in a bioreactor.
  • the gradual addition of a fresh volume of selected nutrients during the growth cycle is used to improve productivity and growth.
  • the product typically a monoclonal antibody or a recombinant protein, is recovered after the culture is harvested.
  • Separating the cells, cell debris and other waste products from the desired product is currently performed using various types of filters for separation. Such filters are expensive and become clogged and non-functional as the bioreactor material is processed.
  • a fed-batch bioreactor also has high start-up costs, and generally requires a large volume to obtain a cost-effective amount of product at the end of the growth cycle, and such processes include large amounts of non-productive downtime.
  • a perfusion bioreactor processes a continuous supply of fresh media that is fed into the bioreactor while growth-inhibiting byproducts are constantly removed. The nonproductive downtime can be reduced or eliminated with a perfusion bioreactor process.
  • the cell densities achieved in perfusion culture (30-100 million cells/mL) are typically higher than for fed-batch modes (5-25 million cells/mL).
  • a perfusion bioreactor requires a cell retention device to prevent escape of the culture when byproducts are being removed.
  • These cell retention systems add a level of complexity to the perfusion process, requiring management, control, and maintenance for successful operation. Operational issues such as malfunction or failure of the cell retention equipment has previously been a problem with perfusion bioreactors. This has limited their attractiveness in the past.
  • US 2014/0154795 A1 discloses a bioreactor that is coupled to a subsequent filtering device that uses an ultrasonic transducer for separation purposes.
  • WO 2014/046605 A1 also describes an acoustic separation method.
  • US 2014/0329997 A1 discloses the use of acoustic standing waves for harvesting biomolecules produced by a cell culture.
  • the present disclosure relates, in various embodiments, to systems for producing biomolecules such as recombinant proteins or monoclonal antibodies, and to processes for separating these desirable products from a cell culture in a bioreactor.
  • the bioreactor includes a device for producing multi-dimensional standing waves. The standing waves are used to hold a cell culture in place. A nutrient fluid stream is circulated through the bioreactor past the cell culture to collect biological products / biomolecules produced by the cell culture. The biomolecules can then be separated / harvested from the nutrient fluid stream away from the cell culture.
  • biomolecules may include viruses, exosomes or phytochemicals.
  • the present disclosure also relates, in various other embodiments, to systems and processes for generating biological cells for use in applications such as, for example, cell therapy.
  • a nutrient fluid stream is flowed through the bioreactor past the cell culture at a rate that is sufficient to dislodge cells from the cell culture.
  • These dislodged biological cells can then be separated / harvested from the nutrient fluid stream to obtain the cells themselves.
  • the cells are plant cells used for bio-agriculture techniques, for example in the production of phytochemicals or insect resistant plants.
  • a system comprising a bioreactor.
  • the bioreactor includes a reaction vessel, an agitator, a feed inlet, and an outlet.
  • a growth volume within the reaction vessel is defined by at least one ultrasonic transducer and a reflector located opposite the at least one ultrasonic transducer.
  • the at least one ultrasonic transducer is driven to produce a multi-dimensional standing wave in the reaction vessel within the growth volume.
  • the outlet of the bioreactor may lead to an external filtering device or to a further purification process such as cell washing, cell concentration or cell fractionation.
  • the bioreactor may also contain a scaffolding or similar structures for the cells to grow upon.
  • the acoustic standing wave internal to the bioreactor may be utilized to both separate the cells from the scaffolding and to collect the cells after the separation.
  • Also disclosed herein are processes for continuously collecting cells from a cell culture comprising: suspending the cell culture in a growth volume of the bioreactor, the bioreactor including at least one ultrasonic transducer and a reflector located opposite the at least one ultrasonic transducer, the at least one ultrasonic transducer being driven to produce a multi-dimensional acoustic standing wave that holds the cell culture in the growth volume; and flowing a nutrient fluid stream through the cell culture to dislodge cells from the cell culture; and separating the dislodged cells from the nutrient fluid stream.
  • the dislodged cells may be separated from the nutrient fluid stream in an external filtering device having a product outlet and a recycle outlet. The cells are recovered through the product outlet, and the nutrient fluid stream exits the external filtering device through a recycle outlet.
  • the bioreactor may further comprise a secondary filtering system located between the growth volume and a bioreactor outlet.
  • the secondary filtering system is activated if the multi-dimensional acoustic standing wave fails.
  • the multi-dimensional acoustic standing wave is generally operated in resonance.
  • the bioreactor may have an array of elements that form the ultrasonic transducer.
  • each ultrasonic transducer may produce a plurality of multi-dimensional acoustic standing waves.
  • the bioreactor does not include an impeller (i.e a physical agitator) within the growth volume.
  • the cell culture is, in particular embodiments, composed of Chinese hamster ovary (CHO) cells. The biomolecules produced thereby can be monoclonal antibodies or recombinant proteins.
  • the cell culture is composed of T cells, genetically modified T-cells, B cells, or NK cells. These biological cells are cultured in the bioreactor for continuous production and recovery of the cells themselves. The recovered cells can then be used for cell therapy (e.g., inoculation of a patient with T-cell / CAR T-cell therapy).
  • the multi-dimensional acoustic standing wave may have an axial force component and a lateral force component which are of the same order of magnitude.
  • the bioreactor can be operated as a perfusion bioreactor.
  • the bioreactor can include a jacket that is used to regulate the temperature of the fluid in the growth volume.
  • the ultrasonic transducer comprises a piezoelectric material that can vibrate in a higher order mode shape.
  • the piezoelectric material may have a square or rectangular or non-symmetrical polygon shape.
  • the ultrasonic transducer may comprise: a housing having a top end, a bottom end, and an interior volume; and a crystal at the bottom end of the housing having an exposed exterior surface and an interior surface, the crystal being able to generate acoustic waves when driven by an electrical signal.
  • a backing layer contacts the interior surface of the crystal, the backing layer being made of a substantially acoustically transparent material.
  • the substantially acoustically transparent material can be balsa wood, cork, or foam.
  • the substantially acoustically transparent material may have a thickness of up to 1 inch.
  • the substantially acoustically transparent material can be in the form of a lattice.
  • an exterior surface of the crystal is covered by a wear surface material with a thickness of a half wavelength or less, the wear surface material being a urethane, epoxy, or silicone coating.
  • the exterior surface of the crystal may also have wear surface formed from a matching layer or wear plate of material adhered to the exterior surface of the crystal.
  • the matching layer or wear plate may be composed of aluminum oxide.
  • the crystal has no backing layer or wear layer.
  • the ultrasonic transducer may also comprise a piezoelectric material that is polymeric such as polyvinylidene fluoride (PVDF).
  • PVDF polyvinylidene fluoride
  • the PVDF may be excited at higher frequencies up to the hundreds of megahertz range such that very small particles may be trapped by the acoustic standing wave.
  • the multi-dimensional acoustic standing wave can be a three-dimensional standing wave.
  • the reflector and/or the ultrasonic transducer may have a non-planar surface.
  • the terms “upper” and “lower” are relative to each other in location, i.e. an upper component is located at a higher elevation than a lower component in a given orientation, but these terms can change if the device is flipped.
  • the terms “inlet” and “outlet” are relative to a fluid flowing through them with respect to a given structure, e.g. a fluid flows through the inlet into the structure and flows through the outlet out of the structure.
  • upstream and “downstream” are relative to the direction in which a fluid flows through various components, i.e. the flow fluids through an upstream component prior to flowing through the downstream component. It should be noted that in a loop, a first component can be described as being both upstream of and downstream of a second component.
  • horizontal and vertical are used to indicate direction relative to an absolute reference, i.e. ground level. However, these terms should not be construed to require structures to be absolutely parallel or absolutely perpendicular to each other. For example, a first vertical structure and a second vertical structure are not necessarily parallel to each other.
  • upwards and downwards are also relative to an absolute reference; an upwards flow is always against the gravity of the earth.
  • Two numbers are of the same order of magnitude if the quotient of the larger number divided by the smaller number is a value of at least 1 and less than 10.
  • agitator is used herein to refer to any device or system which can be used to cause mixing of a fluid volume, such that material in the fluid volume is dispersed and becomes more homogeneous.
  • the term “impeller” is used to refer to a physical agitator, such as a blade. Examples of agitators which are not impellers may include aerators (which use air).
  • crystal refers to a single crystal or polycrystalline material that is used as a piezoelectric material.
  • Bioreactors are useful for making biomolecules such as recombinant proteins or monoclonal antibodies.
  • cells are cultured in a bioreactor vessel with media in order to produce the desired product, and the desired product is then harvested by separation from the cells and media.
  • mammalian cell cultures including Chinese hamster ovary (CHO), NS0 hybridoma cells, baby hamster kidney (BHK) cells, and human cells has proven to be a very efficacious way of producing/expressing the recombinant proteins and monoclonal antibodies required of today's pharmaceuticals.
  • a perfusion bioreactor process Two general types of bioreactor processes exist: fed-batch and perfusion. Many factors favor the use of a perfusion bioreactor process. The capital and start-up costs for perfusion bioreactors are lower, smaller upstream and downstream capacity is required, and the process uses smaller volumes and fewer seed steps than fed-batch methods. A perfusion bioreactor process also lends itself better to development, scale-up, optimization, parameter sensitivity studies, and validation.
  • the present disclosure relates to the generation of three-dimensional (3-D) or multi-dimensional acoustic standing waves from one or more piezoelectric transducers, where the transducers are electrically or mechanically excited such that they move in a "drumhead” or multi-excitation mode (i.e., multi-mode displacement pattern), rather than a "piston” or single excitation mode fashion.
  • the types of waves thus generated can be characterized as composite waves, with displacement profiles that are similar to leaky symmetric (also referred to as compressional or extensional) Lamb waves. The waves are leaky because they radiate into the water layer, which result in the generation of the acoustic standing waves in the water layer.
  • Symmetric Lamb waves have displacement profiles that are symmetric with respect to the neutral axis of the piezoelectric element, which causes multiple standing waves to be generated in a 3-D space.
  • a higher lateral trapping force is generated than if the piezoelectric transducer is excited in a "piston" mode where only a single, planar standing wave is generated.
  • the 3-D or multi-dimensional acoustic standing waves can have a higher lateral trapping force which may be up to and beyond 10 times stronger than a single, planar acoustic standing wave generated in piston mode.
  • the input power is tunable for a controlled flow. This can be used to hold the cell culture within a defined volume (referred to herein as a "growth volume”) while the fluid contents and desired byproducts are removed.
  • Acoustophoresis is a low-power, no-pressure-drop, no-clog, solid-state approach to separate solids from fluids, i.e. it is used to achieve separations that are more typically performed with porous filters, but it has none of the disadvantages of filters.
  • the present disclosure provides bioreactors that operate at the macro-scale to separate cell cultures in flowing systems with high flow rates.
  • the bioreactor uses a high intensity three dimensional ultrasonic standing wave that results in an acoustic radiation force that is larger than and can overcome the combined effects of fluid drag and buoyancy or gravity at certain flow rates, and is therefore able to trap (i.e., hold in place) a suspended phase (i.e. cells and cell cultures) in the standing wave.
  • the retained cells may clump or agglomerate.
  • a nutrient fluid stream can then be flowed/circulated through the cell culture to provide nutrition and oxygenation to the cells, and to capture the biomolecules produced by the cells.
  • the standing waves are also believed to stimulate the cell culture, so as to increase the rate of expression of the desired biomolecules.
  • This provides a self-contained "acoustic bioreactor" where the biomolecules may be continuously harvested, and at an accelerated rate, from the cell culture.
  • the present systems have the ability to create acoustic ultrasonic standing wave fields that can hold the cell cultures in place in a flow field with a linear velocity ranging from 0.1 mm/sec to velocities exceeding 1 cm/s.
  • the trapping capability of a standing wave may be varied as desired, for example by varying the flow rate of the fluid, the acoustic radiation force, and the shape of the bioreactor to maximize cell retention.
  • the multi-dimensional ultrasonic acoustic standing waves can be used to trap, i.e., hold stationary, a cell culture in a fluid stream (e.g. cell culture medium or nutrient fluid stream).
  • a fluid stream e.g. cell culture medium or nutrient fluid stream.
  • the scattering of the acoustic field off the cells results in a three dimensional acoustic radiation force, which acts as a three-dimensional trapping field.
  • the acoustic radiation force is proportional to the particle volume (e.g. the cube of the radius) when the particle is small relative to the wavelength. It is proportional to frequency and the acoustic contrast factor.
  • acoustic energy e.g. the square of the acoustic pressure amplitude
  • sinusoidal spatial variation of the force is what drives the cells to the stable positions within the standing waves.
  • the acoustic radiation force exerted on the cell is stronger than the combined effect of fluid drag force and buoyancy/gravitational force, the cell is trapped within the acoustic standing wave field.
  • the action of the acoustic forces (i.e., the lateral and axial acoustic forces) on the trapped cells results in concentration, clustering, clumping, agglomeration and/or coalescence.
  • the 3-D or multi-dimensional acoustic standing wave(s) is operated at a voltage and frequency such that the biomolecule-producing cell culture, such as Chinese hamster ovary cells (CHO cells), the most common host for the industrial production of recombinant protein therapeutics, are held in place by the ultrasonic standing wave, i.e., remain in a stationary position.
  • the CHO cells are trapped in the minima of the acoustic radiation potential.
  • Most biological cell types present a higher density and lower compressibility than the medium in which they are suspended, so that the acoustic contrast factor between the cells and the medium has a positive value.
  • the axial acoustic radiation force drives the biological cells towards the standing wave pressure nodes.
  • the axial component of the acoustic radiation force drives the cells, with a positive contrast factor, to the pressure nodal planes, whereas cells or other particles with a negative contrast factor are driven to the pressure anti-nodal planes.
  • the radial or lateral component of the acoustic radiation force helps trap the cells.
  • the radial or lateral component of the ARF is larger than the combined effect of fluid drag force and gravitational force.
  • F LRF F D + F B .
  • this equation can be used to estimate the magnitude of the lateral acoustic radiation force.
  • Gor'kov's theory is limited to cell sizes that are small with respect to the wavelength of the sound fields in the fluid and the cell, and it also does not take into account the effect of viscosity of the fluid and the cell on the radiation force.
  • Additional theoretical and numerical models have been developed for the calculation of the acoustic radiation force for a cell without any restriction as to size relative to wavelength. These models also include the effect of fluid and cell viscosity, and therefore are a more accurate calculation of the acoustic radiation force.
  • the models that were implemented are based on the theoretical work of Yurii Ilinskii and Evgenia Zabolotskaya as described in AIP Conference Proceedings, Vol. 1474-1, pp. 255-258 (2012 ).
  • Additional in-house models have been developed to calculate acoustic trapping forces for cylindrical shaped objects, such as the "hockey pucks" of trapped particles in the standing wave, which closely resemble a cylinder.
  • the lateral force component of the total acoustic radiation force (ARF) generated by the ultrasonic transducer(s) of the present disclosure is significant and is sufficient to overcome the fluid drag force at linear velocities of up to 1 cm/s and beyond, and to create tightly packed clusters, and is of the same order of magnitude as the axial force component of the total acoustic radiation force.
  • This lateral ARF can thus be used to retain cells in a particular volume of a bioreactor while the bioreactor process continues. This is especially true for a perfusion bioreactor.
  • the expressed materials are composed of biomolecules such as recombinant proteins or monoclonal antibodies, and are the desired product to be recovered.
  • the standing waves can be used to trap the cells and cell debris present in the cell culture media.
  • the cells having a positive contrast factor, move to the nodes (as opposed to the anti-nodes) of the standing wave.
  • As the cells agglomerate at the nodes of the standing wave there is also a physical scrubbing of the cell culture media that occurs whereby more cells are trapped as they come in contact with the cells that are already held within the standing wave. This generally separates the cells from the cell culture media.
  • the expressed biomolecules remain in the nutrient fluid stream (i.e. cell culture medium).
  • the ultrasonic transducer(s) generate a three-dimensional or multi-dimensional acoustic standing wave in the fluid that exerts a lateral force on the suspended particles to accompany the axial force so as to increase the particle trapping capabilities of the standing wave.
  • Typical results published in literature state that the lateral force is two orders of magnitude smaller than the axial force.
  • the technology disclosed in this application provides for a lateral force to be of the same order of magnitude as the axial force.
  • a perfusion bioreactor may also be used to generate cells that can subsequently be used for autologous and/or allogeneic cell therapy.
  • the biological cells to be used in the cell therapy are cultured in the bioreactor and expanded (i.e. to increase the number of cells in the bioreactor through cell reproduction).
  • These cells may be lymphocytes such as T cells (e.g., CAR T-cells, Jurkat T-cells), B cells, or NK cells; their precursors, such as peripheral blood mononuclear cells (PBMCs); genetically modified T-cells, such as CAR T-cells; and the like.
  • the acoustic standing wave is used to hold the cell culture within the bioreactor.
  • the cell culture reproduces as it is held by the acoustic standing wave.
  • a nutrient fluid stream is then flowed through the cell culture, dislodging some of the cells and leaving the remainder of the cell culture within the acoustic standing wave.
  • the dislodged cells that are carried away from the cell culture by the nutrient fluid stream can subsequently be separated and purified for use in cell therapy.
  • the acoustic acoustic standing wave acts as a cell retention mechanism.
  • the acoustic cell retention systems described herein can operate over a range of cell recirculation rates, efficiently retain cells over a range of perfusion (or media removal) rates, and can be tuned to fully retain or selectively pass some percentage of cells through fluid flow rate, transducer power or frequency manipulation. Power and flow rates can all be monitored and used as feedback in an automated control system.
  • the bioreactors of the present disclosure are designed to maintain a high intensity multi-dimensional acoustic standing wave.
  • the device is driven by a function generator and amplifier (not shown).
  • the device performance is monitored and controlled by a computer. It may be desirable, at times, due to acoustic streaming, to modulate the frequency or voltage amplitude of the standing wave. This modulation may be done by amplitude modulation and/or by frequency modulation.
  • Figure 1 illustrates a single standing wave system 100 that is comprised of a reflector plate 101 and an ultrasonic transducer 103 that is set to resonate so as to form a standing wave 102.
  • Excitation frequencies typically in the range from hundreds of kHz to tens of MHz are applied by the transducer 103.
  • One or more standing waves are created between the transducer 103 and the reflector 101.
  • the standing wave is the sum of two propagating waves that are equal in frequency and intensity and that are traveling in opposite directions, i.e. from the transducer to the reflector and back.
  • the propagating waves destructively interfere with each other and thus generate the standing wave.
  • a dotted line 105 is used to indicate the amplitude.
  • a node is a point where the wave has minimum amplitude, and is indicated with reference numeral 107.
  • An anti-node is a point where the wave has maximum amplitude, and is indicated with reference numeral 109.
  • FIG. 2 is a schematic diagram that compares a conventional fed-batch bioreactor system 201 (left side) with a conventional perfusion bioreactor system 202 (right side).
  • the bioreactor 210 includes a reaction vessel 220.
  • the cell culture media is fed to the reaction vessel through a feed inlet 222.
  • An agitator 225 is used to circulate the media throughout the cell culture.
  • the agitator is depicted as a set of rotating blades, though any type of system that causes circulation is contemplated.
  • the bioreactor permits growth of a seed culture through a growth / production cycle, during which time debris, waste and unusable cells will accumulate in the bioreactor and the desired product (e.g.
  • the reaction vessel 220 also includes an outlet 224 for removing material.
  • the bioreactor includes a reaction vessel 220 with a feed inlet 222 for the cell culture media.
  • An agitator 225 is used to circulate the media throughout the cell culture.
  • An outlet 224 of the reaction vessel is fluidly connected to the inlet 232 of a filtering device 230, and continuously feeds the media (containing cells and desired product) to a filtering device.
  • the filtering device 230 is located downstream of the reaction vessel, and separates the desired product from the cells.
  • the filtering device 230 has two separate outlets, a product outlet 234 and a recycle outlet 236.
  • the product outlet 234 fluidly connects the filtering device 230 to a containment vessel 240 downstream of the filtering device, which receives a concentrated flow of the desired product (plus media) from the filtering device. From there, further processing / purification can occur to isolate / recover the desired product.
  • the recycle outlet 236 fluidly connects the filtering device 230 back to a recycle inlet 226 of the reaction vessel 220, and is used to send the cells and cell culture media back into the reaction vessel for continued growth / production. Put another way, there is a fluid loop between the reaction vessel and the filtering device.
  • the reaction vessel 220 in the perfusion bioreactor system 202 has a continuous throughput of product and thus can be made smaller than the fed-batch bioreactor system 201.
  • the filtering process is critical to the throughput of the perfusion bioreactor. A poor filtering process will allow for only low throughput and result in low yields of the desired product.
  • FIG. 3 is a cross-sectional view of a bioreactor 300 used in the systems of the present disclosure.
  • the bioreactor includes a reaction vessel 320 having an internal volume 323.
  • a feed inlet 322 at the top of the vessel is used to feed a nutrient fluid stream into the vessel, and can also be used to feed in additional cells for maintaining the cell culture.
  • An agitator 325 is present in the form of an impeller blade.
  • An outlet 324 is shown at the bottom of the vessel.
  • An aerator (not shown) can be used to provide gas to the internal volume.
  • Sensors 314 are shown at the top right of the vessel.
  • a pump 316 is illustrated for feeding the nutrient fluid stream into the vessel, as is another pump 318 for removing the nutrient fluid stream from the vessel.
  • These pumps are used to circulate the nutrient fluid stream through the cell culture and furnish nutrition and oxygenation to keep the cells viable and productive.
  • the pumps also deliver the produced biomolecules to another portion of the bioreactor (not shown) where these biomolecules can be further filtered and separated downstream of the reaction vessel.
  • the reaction vessel also includes an ultrasonic transducer 330 on one side of the vessel, and a reflector 332 located on another side opposite the ultrasonic transducer.
  • a growth volume 334 is present between the transducer and the reflector (illustrated with dotted lines).
  • a multi-dimensional standing wave (not shown) is generated between the transducer and the reflector that holds the cell culture in the growth volume. It is noted that the growth volume 334 is a portion of the internal volume 323. It is also noted that the blade of the agitator 325 is not located within the growth volume 334, because its presence can disrupt the standing wave
  • a thermal jacket 310 surrounds the reaction vessel, and is used to regulate the temperature of the internal volume 323 and the cell culture. In this regard, it is usually desirable to maintain the temperature of the cell culture below 38°C to prevent compromise of the cells.
  • the thermal jacket is usually a chilling system used to mitigate any excess heat generated by the ultrasonic transducers. It is noted that the thermal jacket typically contains a temperature-regulating fluid. The standing wave created by the transducer 330 and reflector 332 can propagate through the jacket and the temperature-regulating fluid therein, and still continue to operate in the reaction vessel to hold the cell culture in place.
  • a secondary filtering system 312 is located between the growth volume 334 and the outlet 324. It is contemplated that in the event the standing waves fail to hold the cell culture in place, the secondary filtering system will operate to keep the cell culture within the reaction vessel and maintain their separation from the produced biomolecules. This could occur, for example, if a high percentage of the ultrasonic transducers fail, or if resonance is lost, or if the power is cut off to the reaction vessel.
  • the nutrient fluid stream is added into the reaction vessel through the feed inlet 322.
  • the contents of the reaction vessel are mixed with the agitator 325.
  • the desired product e.g. biomolecules
  • the nutrient fluid stream, containing the biomolecular product is drawn from the reaction vessel through outlet 324. From there, the nutrient fluid stream can be processed to isolate the desired product.
  • any cells and the nutrient fluid can be recycled back to the reaction vessel.
  • the present disclosure should not be construed as stating that no cells ever escape the standing wave and the growth volume.
  • reaction vessel inlet 322 is depicted at the top of the vessel and the outlet 324 is depicted at the bottom of the vessel. This arrangement can be reversed if desired, for example depending on the desired product to be obtained.
  • the cell culture When the bioreactor is operated to produce additional cells for use in cell therapy, again, the cell culture is held within the growth volume 334 by the acoustic standing wave, and the cell culture reproduces / expands.
  • the nutrient fluid stream flows through the growth volume and dislodges some cells from the cell culture. These dislodged cells are then drawn from the reaction vessel through outlet 324.
  • the cells can subsequently be separated from the nutrient fluid stream using downstream processes.
  • the dislodged cells may include viable cells, nonviable cells, cell fragments, etc., and it is the viable cells that are desired to be recovered.
  • One example of a downstream process that can be used for some purification purposes is the external filtering device 230 illustrated in Figure 2 . This process can be performed continuously.
  • Figure 4 is another illustration of the reaction vessel 420 of a bioreactor.
  • the reaction vessel is tubular, with the outlet at the top and the inlet at the bottom of the vessel, with fluid flow being indicated by arrows 405.
  • An array of transducers 430 is arranged vertically on one side, and an array of reflectors 432 is arranged on an opposite side from the transducers. Waves 401 are transmitted from the transducer to the reflector, and waves 402 bounce back from the reflector to the transducer.
  • the cell culture is held in place at the nodes of the standing wave thus generated, and is indicated with reference number 403.
  • a flexible bag or pouch is used as the bioreactor.
  • a bioreactor is illustrated in Figure 15 .
  • the interior volume of the flexible bag 700 operates as the growth volume for cells.
  • the flexible bag includes an inlet 702 and an outlet 704.
  • Opposite surfaces of the flexible bag can be stiff.
  • One surface includes an ultrasonic transducer 710, and the opposite surface includes a reflector 712 opposite the transducer, so that a multi-dimensional acoustic standing wave can be generated within the bag.
  • Only one inlet and outlet are illustrated here.
  • other parts of the bioreactor that are shown in Figure 3 , such as the agitator, pump, sensors, thermal jacket, etc., though such parts can be used with the bag of Figure 15 .
  • cell culture media and cells drawn from a cell source enter the bag through the inlet.
  • the multi-dimensional acoustic standing wave generated by the transducer traps the cell culture within the bag.
  • Fluid such as cell culture media and other material, are then flowed through the inlet and subsequently exit through the outlet of the bag. That added fluid can dislodge cells from the cell culture trapped in the acoustic standing wave, or can be used to remove biomolecules being expressed by the trapped cell culture.
  • the bioreactor includes a rigid housing.
  • a rigid housing This may take the form of a plastic, glass or metal container such as that depicted in Figure 3 .
  • the rigid housing contains all of the various parts, including the ultrasonic transducer and the reflector.
  • a flexible polymeric bag or pouch with appropriate connections, like that illustrated in Figure 15 is placed within the rigid housing and connected to the various inlets, outlets, and other components.
  • the flexible bag itself contains an inlet and an outlet.
  • This flexible bag or pouch is similar to the bag 700 of Figure 15 , but does not have the ultrasonic transducer and reflector attached thereto.
  • the cell culture is maintained within the flexible bag.
  • it is desired to change the cell culture e.g.
  • the bag containing the cell culture can then be removed and a new bag placed within the rigid housing. This provides for faster turnaround of the bioreactor to making new product, and keeps the process as a closed system so that the cell culture does not become contaminated.
  • the reaction vessel may be tubular, cubic, or another polygonal shape.
  • the flow of the nutrient fluid stream through the reaction vessel of the bioreactor may be vertical, horizontal, or any angle in between.
  • the combination of the ultrasonic transducers and the reflectors set up the resonant waves in the interior of the reaction vessel.
  • the standing waves hold the cell culture at their net zero pressure nodes.
  • the ultrasonic transducers and reflectors may be set perpendicular or at another angle to the fluid flow of the nutrient fluid stream through the acoustic bioreactor. This will allow for greater holding strength of the acoustic standing wave for the cell culture.
  • the reflector may be a passive shape that is flat or is non-planar, or alternatively may itself be an active piezoelectric element that can change its shape to maintain resonance, but cannot itself generate an acoustic wave.
  • CAR T-cells are one example of genetically modified T-cells that can be obtained using the devices and processes of the present disclosure.
  • the CAR T-cell therapy process involves lymphocytes that have been separated from the whole blood of either the patient receiving the therapy, known as autologous therapy, or from a group of individuals, known as allogeneic therapy. Lymphocytes, a subtype of white blood cells, comprise a major portion of the immune system.
  • lymphocytes There are three types of lymphocytes: 1) B lymphocytes (B cells) make antibodies to fight infection 2) T lymphocytes (T-cells) and 3) natural killer (NK) cells.
  • B cells B lymphocytes
  • T-cells T lymphocytes
  • NK natural killer cells.
  • the T-cells and the NK cells directly kill infected or cancerous cells and also talk to other cells of the immune system using chemicals known as "cytokines.”
  • Immunotherapy is a type of treatment that utilizes the body's own immune system to fight cancer. It improves the body's ability to detect and kill cancer cells and it is based on the concept that immune cells or antibodies can recognize and kill cancer cells.
  • T-cells are collected from a patient (step 900) via apheresis, a process that withdraws blood from the body and removes one or more blood components (such as plasma, platelets or white blood cells). The remaining blood is then returned back into the body.
  • the extracted T-cells can be cultured and expanded (step 902 ) .
  • the T-cells are then sent to a laboratory or a drug manufacturing facility where they are genetically engineered to produce chimeric antigen receptors (CARs) on their surface (step 904 ) .
  • CARs chimeric antigen receptors
  • CAR chimeric antigen receptor
  • the reengineered CAR T-cells are then "expanded” or multiplied (step 906 ) .
  • the number of the patient's genetically modified T-cells is “expanded” by growing cells in the laboratory until there are many millions of them. These CAR T-cells are frozen and, when there are enough of them, they are sent to the hospital or center where the patient is being treated.
  • the CAR T-cells are then infused into the patient (step 908 ) .
  • Many patients are given a brief course of one or more chemotherapy agents before they receive the infusion of CAR T-cells in a process that is called preconditioning.
  • the preconditioning process suppresses the response of the patients on modified T-cells so that the CAR T-cells that have been returned to the patient's bloodstream may be more effective and multiply in number.
  • These are the "attacker" cells that will recognize, and kill, cancerous cells that have the targeted antigen on their surface.
  • the CAR T-cells guard the patient against recurrence of the targeted cancer.
  • CAR T-cells may remain in the body long after the infusion has been completed. They guard against cancer recurrence, so the therapy frequently results in long-term remissions as opposed to chemotherapy or monoclonal antibody therapy that requires continuous inoculations of the patient.
  • the acoustic bioreactors of the present disclosure can be used in at least two steps in the process.
  • the acoustic bioreactors can be used for expanding the T-cells prior to their engineering (step 902 ) .
  • the acoustic bioreactors can be used to expand the CAR T-cells prior to being administered back to the patient (step 906 ) .
  • These acoustic bioreactors can be in the form of a bag, as illustrated in Figure 15 .
  • FIG. 5 is a cross-sectional diagram of a conventional ultrasonic transducer.
  • This transducer has a wear plate 50 at a bottom end, epoxy layer 52, ceramic crystal 54 (made of, e.g. Lead Zirconate Titanate (PZT)), an epoxy layer 56, and a backing layer 58.
  • PZT Lead Zirconate Titanate
  • the epoxy layer 56 attaches backing layer 58 to the crystal 54.
  • the entire assembly is contained in a housing 60 which may be made out of, for example, aluminum.
  • An electrical adapter 62 provides connection for wires to pass through the housing and connect to leads (not shown) which attach to the crystal 54.
  • backing layers are designed to add damping and to create a broadband transducer with uniform displacement across a wide range of frequency and are designed to suppress excitation at particular vibrational eigen-modes.
  • Wear plates are usually designed as impedance transformers to better match the characteristic impedance of the medium into which the transducer radiates. However, the oscillating pressure and heating of the crystal can cause the wear plate to separate from the crystal.
  • FIG 8 is a cross-sectional view of an ultrasonic transducer 81 of the present disclosure, which is used in the acoustophoretic filtering devices of the present disclosure.
  • Transducer 81 has an aluminum housing 82.
  • a PZT crystal 86 defines the bottom end of the transducer, and is exposed from the exterior of the housing.
  • the crystal is supported on its perimeter by a small elastic layer 98, e.g. silicone or similar material, located between the crystal and the housing. Put another way, no wear layer is present.
  • the housing may also be composed of a more electrically conductive material, such as steel.
  • the housing may also be grounded to the negative side of the transducer.
  • Screws attach an aluminum top plate 82a of the housing to the body 82b of the housing via threads 88 .
  • the top plate includes a connector 84 to pass power to the PZT crystal 86.
  • the bottom and top surfaces of the PZT crystal 86 are each connected to an electrode (positive and negative), such as silver or nickel.
  • a wrap-around electrode tab 90 connects to the bottom electrode and is isolated from the top electrode. Electrical power is provided to the PZT crystal 86 through the electrodes on the crystal, with the wrap-around tab 90 being the ground connection point.
  • the crystal 86 has no backing layer or epoxy layer as is present in Figure 5 .
  • there is an air gap 87 in the transducer between aluminum top plate 82a and the crystal 86 i.e. the air gap is completely empty).
  • a minimal backing 58 and/or wear plate 50 may be provided in some embodiments, as seen in Figure 9 .
  • the transducer design can affect performance of the system.
  • a typical transducer is a layered structure with the ceramic crystal bonded to a backing layer and a wear plate. Because the transducer is loaded with the high mechanical impedance presented by the standing wave, the traditional design guidelines for wear plates, e.g., half wavelength thickness for standing wave applications or quarter wavelength thickness for radiation applications, and manufacturing methods may not be appropriate. Rather, in one embodiment of the present disclosure the transducers, there is no wear plate or backing, allowing the crystal to vibrate in one of its eigenmodes with a high Q-factor. The vibrating ceramic crystal/disk is directly exposed to the fluid flowing through the flow chamber.
  • Removing the backing also permits the ceramic crystal to vibrate at higher order modes of vibration with little damping (e.g. higher order modal displacement).
  • the crystal vibrates with a more uniform displacement, like a piston.
  • Removing the backing allows the crystal to vibrate in a non-uniform displacement mode.
  • the higher order the mode shape of the crystal the more nodal lines the crystal has.
  • the higher order modal displacement of the crystal creates more trapping lines, although the correlation of trapping line to node is not necessarily one to one, and driving the crystal at a higher frequency will not necessarily produce more trapping lines.
  • the crystal may have a backing that minimally affects the Q-factor of the crystal (e.g. less than 5%).
  • the backing may be made of a substantially acoustically transparent material such as balsa wood, foam, or cork which allows the crystal to vibrate in a higher order mode shape and maintains a high Q-factor while still providing some mechanical support for the crystal.
  • the backing layer may be a solid, or may be a lattice having holes through the layer, such that the lattice follows the nodes of the vibrating crystal in a particular higher order vibration mode, providing support at node locations while allowing the rest of the crystal to vibrate freely.
  • the goal of the lattice work or acoustically transparent material is to provide support without lowering the Q-factor of the crystal or interfering with the excitation of a particular mode shape.
  • Placing the crystal in direct contact with the fluid also contributes to the high Q-factor by avoiding the dampening and energy absorption effects of the epoxy layer and the wear plate.
  • Other embodiments may have wear plates or a wear surface to prevent the PZT, which contains lead, contacting the host fluid. This may be desirable in, for example, biological applications such as separating blood. Such applications might use a wear layer such as chrome, electrolytic nickel, or electroless nickel. Chemical vapor deposition could also be used to apply a layer of poly(p-xylylene) (e.g. Parylene) or other polymer. Organic and biocompatible coatings such as silicone or polyurethane are also usable as a wear surface.
  • the ultrasonic transducer has a 1 inch diameter and a nominal 2 MHz resonance frequency. Each transducer can consume about 28 W of power for droplet trapping at a flow rate of 3 GPM. This translates to an energy cost of 0.25 kW hr/ m 3 . This is an indication of the very low cost of energy of this technology. Desirably, each transducer is powered and controlled by its own amplifier. In other embodiments, the ultrasonic transducer uses a square crystal, for example with 1"x1" dimensions. Alternatively, the ultrasonic transducer can use a rectangular crystal, for example with 1"x2.5" dimensions.
  • Power dissipation per transducer was 10 W per 1" ⁇ 1" transducer cross-sectional area and per inch of acoustic standing wave span in order to get sufficient acoustic trapping forces.
  • each 1" ⁇ 1" square transducer consumes 40 W.
  • the larger 1"x2.5" rectangular transducer uses 100W in an intermediate scale system.
  • the array of three 1"x1" square transducers would consume a total of 120 W and the array of two 1"x2.5" transducers would consume about 200 W.
  • Arrays of closely spaced transducers represent alternate potential embodiments of the technology. Transducer size, shape, number, and location can be varied as desired to generate desired three-dimensional acoustic standing wave patterns.
  • FIG 8 is an illustration of a piezoelectric ultrasonic transducer 800 that may also be utilized to generate multiple standing waves.
  • the base 801 of the transducer has an array formed from multiple piezoelectric elements 802 on the surface.
  • These piezoelectric elements may be formed on the surface in a variety of ways, including adhesion of piezoelectric crystals, photomasking and deposition techniques such as those utilized in the electronic industry. For example, the surface of a piezoelectric crystal can be cut in a pattern to a certain depth, and the cut-away areas are then filled with a secondary material to isolate the individual areas to form the resulting pattern on the piezoelectric crystal surface.
  • the size, shape, and thickness of the transducer determine the transducer displacement at different frequencies of excitation, which in turn affects separation efficiency.
  • the transducer is operated at frequencies near the thickness resonance frequency (half wavelength).
  • Gradients in transducer displacement typically result in more trapping locations for the cells/biomolecules.
  • Higher order modal displacements generate three-dimensional acoustic standing waves with strong gradients in the acoustic field in all directions, thereby creating equally strong acoustic radiation forces in all directions, leading to multiple trapping lines, where the number of trapping lines correlate with the particular mode shape of the transducer.
  • Figure 9 shows the measured electrical impedance amplitude of a square transducer as a function of frequency in the vicinity of the 2.2 MHz transducer resonance.
  • the minima in the transducer electrical impedance correspond to acoustic resonances of the water column and represent potential frequencies for operation.
  • Numerical modeling has indicated that the transducer displacement profile varies significantly at these acoustic resonance frequencies, and thereby directly affects the acoustic standing wave and resulting trapping force. Since the transducer operates near its thickness resonance, the displacements of the electrode surfaces are essentially out of phase. The typical displacement of the transducer electrodes is not uniform and varies depending on frequency of excitation.
  • the displacement has a single maximum in the middle of the electrode and minima near the transducer edges.
  • the transducer profile has multiple maxima leading to multiple trapped lines of oil droplets. Higher order transducer displacement patterns result in higher trapping forces and multiple stable trapping lines for the captured oil droplets.
  • the trapping lines of oil droplets were observed and characterized.
  • the characterization involved the observation and pattern of the number of trapping lines across the fluid channel, as shown in Figure 10 , for seven of the ten resonance frequencies identified in Figure 9 .
  • Different displacement profiles of the transducer can produce different (more) trapping lines in the standing waves, with more gradients in displacement profile generally creating higher trapping forces and more trapping lines.
  • Figure 11 is a numerical model showing a pressure field that matches the 9 trapping line pattern.
  • the numerical model is a two-dimensional model; and therefore only three trapping lines are observed. Two more sets of three trapping lines exist in the third dimension perpendicular to the plane of the page.
  • the system is operated at a voltage and frequency such that the cells (that make up the cell culture) are trapped by the ultrasonic standing wave, i.e., remain in a stationary position.
  • the cells are collected along well-defined trapping lines, separated by half a wavelength. Within each nodal plane, the cells are trapped in the minima of the acoustic radiation potential.
  • the axial component of the acoustic radiation force drives cells with a positive contrast factor to the pressure nodal planes, whereas cells with a negative contrast factor are driven to the pressure anti-nodal planes.
  • the radial or lateral component of the acoustic radiation force is the force that traps the cell.
  • the radial or lateral component of the acoustic radiation force is typically several orders of magnitude smaller than the axial component of the acoustic radiation force.
  • the lateral force generated by the transducers of the present disclosure can be significant, on the same order of magnitude as the axial force component, and is sufficient to overcome the fluid drag force at linear velocities of up to 1 cm/s.
  • the lateral force can be increased by driving the transducer in higher order mode shapes, as opposed to a form of vibration where the crystal effectively moves as a piston having a uniform displacement.
  • the acoustic pressure is proportional to the driving voltage of the transducer.
  • the electrical power is proportional to the square of the voltage.
  • the transducer is typically a thin piezoelectric plate, with electric field in the z-axis and primary displacement in the z-axis.
  • the transducer is typically coupled on one side by air (i.e. the air gap within the transducer) and on the other side by the fluid of the cell culture media.
  • the types of waves generated in the plate are known as composite waves.
  • a subset of composite waves in the piezoelectric plate is similar to leaky symmetric (also referred to as compressional or extensional) Lamb waves.
  • the piezoelectric nature of the plate typically results in the excitation of symmetric Lamb waves.
  • the waves are leaky because they radiate into the water layer, which result in the generation of the acoustic standing waves in the water layer.
  • Lamb waves exist in thin plates of infinite extent with stress free conditions on its surfaces. Because the transducers of this embodiment are finite in nature, the actual modal displacements are more complicated.
  • Figure 12 shows the typical variation of the in-plane displacement (x-displacement) and out-of-plane displacement (y-displacement) across the thickness of the plate, the in-plane displacement being an even function across the thickness of the plate and the out-of-plane displacement being an odd function.
  • the displacement components vary across the width and length of the plate.
  • a (m,n) mode is a displacement mode of the transducer in which there are m undulations in transducer displacement in the width direction and n undulations in the length direction, and with the thickness variation as described in Figure 14 .
  • the maximum number of m and n is a function of the dimension of the crystal and the frequency of excitation.
  • the transducers are driven so that the piezoelectric crystal vibrates in higher order modes of the general formula (m, n), where m and n are independently 1 or greater.
  • the transducers will vibrate in higher order modes than (2,2).
  • Higher order modes will produce more nodes and antinodes, result in three-dimensional standing waves in the fluid layer, characterized by strong gradients in the acoustic field in all directions, not only in the direction of the standing waves, but also in the lateral directions.
  • the acoustic gradients result in stronger trapping forces in the lateral direction.
  • driving the transducers to generate multimodal vibrations can generate multiple standing waves from one piezoelectric crystal.
  • the pulsed voltage signal driving the transducer can have a sinusoidal, square, sawtooth, or triangle waveform; and have a frequency of 500 kHz to 10 MHz.
  • the pulsed voltage signal can be driven with pulse width modulation, which produces any desired waveform.
  • the pulsed voltage signal can also have amplitude or frequency modulation start/stop capability to eliminate streaming.
  • the transducer is usually operated so that the acoustic standing wave remains on resonance. A feedback system is generally present for this purpose.
  • the transducer(s) is/are used to create a pressure field that generates forces of the same order of magnitude both orthogonal to the standing wave direction and in the standing wave direction.
  • forces are roughly the same order of magnitude, particles of size 0.1 microns to 300 microns will be moved more effectively towards regions of agglomeration ("trapping lines").
  • regions of agglomeration regions of agglomeration
  • hot spots are located in the maxima or minima of acoustic radiation potential. Such hot spots represent particle collection locations which allow for better wave transmission between the transducer and the reflector during collection and stronger inter-particle forces, leading to faster and better particle agglomeration.
  • Figure 13 and Figure 14 are exploded views showing the various parts of a reaction vessel that uses acoustophoresis to hold cells in place in a growth volume.
  • Figure 15 provides only one chamber for one growth volume, while Figure 16 has two chambers and can have two different growth volumes.
  • fluid enters the reaction vessel 190 through a four-port inlet 191.
  • a transition piece 192 is provided to create plug flow through the chamber 193.
  • a transducer 40 and a reflector 194 are located on opposite walls of the chamber for holding the cell culture in place. Fluid then exits the chamber 193 and the reaction vessel through outlet 195.
  • the growth volume is located in chamber 193.
  • Figure 14 has two chambers 193.
  • a system coupler 196 is placed between the two chambers 193 to join them together.
  • a growth volume can be located in each chamber 193.
  • all of the parts of the system e.g. the reaction vessel, tubing leading to and from the bioreactor, the temperature-regulating jacket, etc.
  • the frequency of the transducers may also be varied to obtain optimal effectiveness for a given power.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Sustainable Development (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (15)

  1. Procédé de collecte en continu de cellules à partir d'une culture cellulaire, comprenant les étapes suivantes :
    suspendre la culture cellulaire dans un volume de croissance d'un bioréacteur, le bioréacteur comprenant au moins un transducteur à ultrasons et un réflecteur situé en face du au moins un transducteur à ultrasons, chaque transducteur à ultrasons étant entraîné pour produire une onde stationnaire acoustique multidimensionnelle qui maintient la cellule culture dans le volume de croissance; et
    faire circuler un flux de fluide nutritif à travers la culture cellulaire pour déloger les cellules de la culture cellulaire ; et
    séparer les cellules délogées du courant de fluide nutritif.
  2. Procédé selon la revendication 1, dans lequel la culture cellulaire est composée de cellules T, de cellules T génétiquement modifiées, de cellules B ou de cellules NK.
  3. Procédé selon la revendication 1, dans lequel les cellules délogées sont séparées du flux de fluide nutritif dans un dispositif de filtration externe, les cellules séparées étant récupérées d'une sortie de produit et le flux de fluide nutritif sortant du dispositif de filtration externe par une sortie de recyclage.
  4. Procédé selon la revendication 1, dans lequel le bioréacteur comprend en outre un système de filtration secondaire situé entre le volume de croissance et une sortie de bioréacteur.
  5. Procédé selon la revendication 4, comprenant en outre l'activation du système de filtrage secondaire en cas de défaillance de l'onde stationnaire acoustique multidimensionnelle.
  6. Procédé selon la revendication 1, comprenant en outre au moins l'une des caractéristiques suivantes :
    l'onde stationnaire acoustique multidimensionnelle est en résonance ;
    le au moins un transducteur ultrasonore est un réseau d'éléments ;
    chaque transducteur ultrasonore produit une pluralité d'ondes stationnaires acoustiques multidimensionnelles ;
    le bioréacteur ne comprend pas d'hélice à l'intérieur du volume de croissance ;
    l'onde stationnaire acoustique multidimensionnelle a une composante de force axiale et une composante de force latérale qui sont du même ordre de grandeur.
  7. Procédé selon la revendication 1, dans lequel le transducteur ultrasonore comprend un matériau piézoélectrique qui peut vibrer dans une forme de mode d'ordre supérieur.
  8. Procédé selon la revendication 7, dans lequel le matériau piézoélectrique a une forme rectangulaire.
  9. Procédé selon la revendication 1, dans lequel le transducteur ultrasonore comprend :
    un boîtier ayant une extrémité supérieure, une extrémité inférieure et un volume intérieur ; et
    un cristal à l'extrémité inférieure du boîtier ayant une surface extérieure exposée et une surface intérieure, le cristal étant capable de vibrer lorsqu'il est entraîné par un signal de tension.
  10. Procédé selon la revendication 9, dans lequel une couche de support est en contact avec la surface intérieure du cristal, la couche de support étant constituée d'un matériau sensiblement acoustiquement transparent.
  11. Procédé selon la revendication 10, comprenant en outre au moins l'une des caractéristiques suivantes :
    le matériau sensiblement acoustiquement transparent est du balsa, du liège ou de la mousse ;
    le matériau sensiblement acoustiquement transparent a une épaisseur allant jusqu'à 1 pouce (2,54 cm) ;
    le matériau sensiblement acoustiquement transparent se présente sous la forme d'un treillis.
  12. Procédé selon la revendication 9, dans lequel une surface extérieure du cristal est recouverte d'un matériau de surface d'usure d'une épaisseur d'une demi-longueur d'onde ou moins, le matériau de surface d'usure étant un revêtement d'uréthane, d'époxyde ou de silicone, ou étant constitué d'oxyde d'aluminium.
  13. Procédé selon la revendication 9, dans lequel le cristal n'a pas de couche de support ou de couche d'usure.
  14. Procédé selon la revendication 1, dans lequel l'onde stationnaire acoustique multidimensionnelle est une onde stationnaire tridimensionnelle.
  15. Procédé de préparation de cellules CAR T à partir d'un patient, comprenant :
    la suspension d'une culture cellulaire dans un volume de croissance d'un bioréacteur, le bioréacteur comprenant au moins un transducteur à ultrasons et un réflecteur situé en face dudit au moins un transducteur à ultrasons, chaque transducteur à ultrasons étant entraîné pour produire une onde stationnaire acoustique multidimensionnelle qui maintient la cellule culture dans le volume de croissance, dans laquelle la culture cellulaire est formée à partir de cellules T qui ont été prélevées sur le patient et génétiquement modifiées en cellules CAR T.
EP16758359.0A 2016-08-23 2016-08-23 Procédés acoustiques associés à des bioréacteurs Active EP3504314B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2016/048243 WO2018038711A1 (fr) 2016-08-23 2016-08-23 Procédés acoustiques associés à des bioréacteurs

Publications (2)

Publication Number Publication Date
EP3504314A1 EP3504314A1 (fr) 2019-07-03
EP3504314B1 true EP3504314B1 (fr) 2021-09-29

Family

ID=56851726

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16758359.0A Active EP3504314B1 (fr) 2016-08-23 2016-08-23 Procédés acoustiques associés à des bioréacteurs

Country Status (5)

Country Link
EP (1) EP3504314B1 (fr)
CN (1) CN109863238A (fr)
CA (1) CA3034801A1 (fr)
ES (1) ES2902047T3 (fr)
WO (1) WO2018038711A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
CA2935960C (fr) 2014-01-08 2023-01-10 Bart Lipkens Dispositif d'acoustophorese avec double chambre acoustophoretique
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11420136B2 (en) 2016-10-19 2022-08-23 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
KR102439221B1 (ko) 2017-12-14 2022-09-01 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
CN111841469A (zh) * 2020-06-08 2020-10-30 董建 一种管式连续流超声反应器

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1285247C (fr) * 1987-05-12 1991-06-25 Marshall D. Graham Enlevement par voie accoustique des particules d'un support aimante
ES2326109B1 (es) * 2007-12-05 2010-06-25 Consejo Superior De Investigaciones Cientificas Microdispositivo de separacion y extraccion selectiva y no invasiva de particulas en suspensiones polidispersas, procedimiento de fabricacion y sus aplicaciones.
US20110154890A1 (en) * 2008-10-08 2011-06-30 Foss Analytical A/S Separation of particles in liquids by use of a standing ultrasonic wave
US9422328B2 (en) * 2012-03-15 2016-08-23 Flodesign Sonics, Inc. Acoustic bioreactor processes
US9416344B2 (en) * 2012-03-15 2016-08-16 Flodesign Sonics, Inc. Bioreactor using acoustic standing waves
US20150253226A1 (en) * 2012-09-21 2015-09-10 Acousort Ab Method for separating cells-bead complexes
KR102132990B1 (ko) * 2012-10-02 2020-07-14 프로디자인 소닉스, 인크. 다-차원 정상파를 사용한 음향영동 분리 기술
CA2900277C (fr) * 2013-02-07 2019-03-26 Bart Lipkens Bioreacteur utilisant des ondes acoustiques stationnaires
CA2918036C (fr) * 2013-07-12 2018-04-24 Thomas J. Kennedy, Iii Procedes acoustiques associes a des bioreacteurs

Also Published As

Publication number Publication date
ES2902047T3 (es) 2022-03-24
WO2018038711A1 (fr) 2018-03-01
CN109863238A (zh) 2019-06-07
EP3504314A1 (fr) 2019-07-03
CA3034801A1 (fr) 2018-03-01

Similar Documents

Publication Publication Date Title
US9688958B2 (en) Acoustic bioreactor processes
EP3504314B1 (fr) Procédés acoustiques associés à des bioréacteurs
EP3019606B1 (fr) Procédés acoustiques associés à des bioréacteurs
US9422328B2 (en) Acoustic bioreactor processes
US10662404B2 (en) Bioreactor using acoustic standing waves
US9783775B2 (en) Bioreactor using acoustic standing waves
US9752114B2 (en) Bioreactor using acoustic standing waves
US10662402B2 (en) Acoustic perfusion devices
EP2953700B1 (fr) Bioréacteur utilisant des ondes acoustiques stationnaires
US9416344B2 (en) Bioreactor using acoustic standing waves
US10689609B2 (en) Acoustic bioreactor processes
US9738866B2 (en) Acoustic perfusion devices
KR102487073B1 (ko) 일정한 유체 유동을 갖는 음파영동 장치
CN109844089B (zh) 使用声驻波的生物反应器
US20170191022A1 (en) Bioreactor using acoustic standing waves
EP3360955A1 (fr) Bioréacteur utilisant des ondes stationnaires acoustiques
EP3234099B1 (fr) Dispositifs acoustiques de perfusion
EP3341463B1 (fr) Dispositifs de perfusion acoustiques

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190320

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20201202

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20210512

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1434210

Country of ref document: AT

Kind code of ref document: T

Effective date: 20211015

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602016064331

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210929

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210929

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211229

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211229

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210929

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210929

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210929

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211230

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2902047

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20220324

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220129

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210929

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210929

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220131

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210929

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210929

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210929

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210929

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602016064331

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210929

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20220615

Year of fee payment: 7

Ref country code: IE

Payment date: 20220609

Year of fee payment: 7

Ref country code: GB

Payment date: 20220630

Year of fee payment: 7

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20220630

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20220715

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20220901

Year of fee payment: 7

Ref country code: DE

Payment date: 20220608

Year of fee payment: 7

Ref country code: AT

Payment date: 20220725

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210929

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20220709

Year of fee payment: 7

Ref country code: BE

Payment date: 20220718

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20220901

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210929

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220823

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220823

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1434210

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210929

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602016064331

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20160823

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20230901

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 1434210

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230823

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230823

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20230823

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210929

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210929

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230823

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230831

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20230831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230901

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230824

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230901

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210929

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210929

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230823

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230823

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230823

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230823

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230831

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210929

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20241003

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230824